Abstract

Amphiphilic block copolymers possess great potential as biomaterials in drug delivery and gene therapy. Herein, pseudopeptidic‐type diblock copolymer of poly(2‐oxazoline)‐block‐polypeptoid (POx‐b‐POI) is presented and synthesized. Poly[2‐(3‐butenyl)‐2‐oxazoline]‐block‐poly(sarcosine) (PBuOx‐b‐PSar) comprising hydrophobic POx segment bearing alkenyl side chain and hydrophilic POI segment of N‐methyl glycine, viz., sarcosine, is prepared by ring‐opening polymerization (ROP) through a one‐pot and three‐step route. Diphenyl phosphate initiates ROP of BuOx, and then the living chain end of PBuOx is quenched by ammonia to obtain PBuOx‐ammonium phosphate in situ, the active ammonium group initiates ROP of sarcosine N‐carboxy anhydride. PBuOx‐b‐PSar with controlled molecular weights (4.7–10.8 kg mol−1) and narrow dispersities (ÐM 1.15–1.21) are characterized by 1H NMR, 13C NMR, and size‐exclusion chromatography. Dynamic light scattering and transmission electron microscopy analysis reveal that PBuOx‐b‐PSar self‐assembles into nanostructures of average diameter DH of 37–109 nm in aqueous solution. 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide test demonstrates the cytocompatibility (relative cell viability > 80%) of the PBuOx‐b‐PSar. In view of the self‐assembly and biocompatibility, the readily prepared diblock copolymers may hopefully be used in biomedical applications. image

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.